Page last updated: 2024-09-23

4,4'-Dihydroxybenzophenone

Cross-References

ID SourceID
PubMed CID69150
CHEMBL ID194859
CHEBI ID34365
SCHEMBL ID18423

Synonyms (74)

Synonym
AC-348
BIDD:ER0179
nsc2831
methanone, bis(4-hydroxyphenyl)-
611-99-4
nsc-2831
bis(p-hydroxy)benzophenone
benzophenone, 4,4'-dihydroxy-
bis(4-hydroxyphenyl) ketone
brn 1874572
p,p'-dihydroxybenzophenone
4,4'-dihydroxydiphenyl ketone
hbp (ketone)
einecs 210-288-1
ai3-00127
nsc 2831
bis(4-hydroxyphenyl)methanone
4,4'-dihydroxybenzophenone
OPREA1_287266
4,4 -dihydroxybenzophenone
compound 0627-0373 (dhbp)
4-[(4-hydroxyphenyl)carbonyl]phenol
bdbm25807
4,4'-dihydroxybenzophenone, 99%
4,4'-dihydoxy-benzophenone
D0577
DB07635
4,4-dihydroxybenzophenone
CHEMBL194859
chebi:34365 ,
STK668062
A833093
NCGC00248695-01
tox21_200550
NCGC00258104-01
4,4'-dihydoxybenzophenone
dtxsid1022425 ,
cas-611-99-4
dtxcid602425
AKOS005206702
4-08-00-02452 (beilstein handbook reference)
hzr7d31sby ,
unii-hzr7d31sby
ccris 9457
4-(4-hydroxybenzoyl)phenol
4,4-dihydroxy benzophenone
FT-0617057
AM20050154
4,4'dihydroxybenzophenone
4,4' dihydroxybenzophenone
4,4'dihydroxy-benzophenone
4,4'-dihydroxybenzophenon
4,4'-dihydroxy benzophenone
bis-(4-hydroxy-phenyl)-methanone
bis(4-hydroxyphenyl)-methanone
4,4'-dihydroxy-benzophenone
SCHEMBL18423
4,4 inverted exclamation mark -dihydroxybenzophenone
SY005681
mfcd00002358
W-105181
sr-01000393027
SR-01000393027-1
GS-3450
4,4'-dihydroxybenzophenone, analytical standard
AC7529
4,4`-dihydroxybenzophenone
CS-W014942
bp_14
Q4637052
bis(4-hydroxy)benzophenone
4,4?-dihydroxybenzophenone
PD005603
HY-W014226

Drug Classes (1)

ClassDescription
benzophenonesAny aromatic ketone in which the carbonyl group is bonded to 2 phenyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency70.97990.007215.758889.3584AID1224835
GLI family zinc finger 3Homo sapiens (human)Potency13.76140.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency29.95220.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency7.37400.000657.913322,387.1992AID1259377; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency36.09710.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency48.55770.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency23.93340.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency43.63580.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency19.70740.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency54.48270.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency28.16420.000229.305416,493.5996AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079
aryl hydrocarbon receptorHomo sapiens (human)Potency36.13810.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency30.63790.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency89.76250.039147.5451146.8240AID1224845
histone deacetylase 9 isoform 3Homo sapiens (human)Potency40.10890.037617.082361.1927AID1259364; AID1259388
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)144.54400.00101.979414.1600AID255211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lanosterol 14-alpha demethylaseMycobacterium tuberculosis H37RvKd28.00000.20000.42001.3000AID351876
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1798586Ligand Binding Assay from Article 10.1128/AAC.00311-07: \\Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.\\2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID752867Inhibition of rabbit skeletal muscle sarco/endoplasmic reticulum calcium ATPase assessed as inhibition of ATP hydrolysis by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Structural requirements for inhibitory effects of bisphenols on the activity of the sarco/endoplasmic reticulum calcium ATPase.
AID351883Binding affinity to Mycobacterium tuberculosis His4-tagged recombinant CYP125 expressed in Escherichia coli HMS174(DE3) by UV-visible spectral titration method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.
AID475505Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID351884Binding affinity to Mycobacterium tuberculosis His4-tagged recombinant CYP130 expressed in Escherichia coli HMS174(DE3) by UV-visible spectral titration method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.
AID351882Binding affinity to Mycobacterium tuberculosis His4-tagged recombinant CYP51 F78L mutant expressed in Escherichia coli HMS174(DE3) by UV-visible spectral titration method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.
AID351879Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 200 uM after 4 days by alamar blue assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.
AID763098Leishmanicidal activity against promastigote form of Leishmania amazonensis MHOM/BR/71973/M2269 after 72 hrs by cell counting2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and biological evaluation against Leishmania amazonensis of a series of alkyl-substituted benzophenones.
AID305980Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by microdilution resazurin assay2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
AID763097Cytotoxicity against mouse peritoneal macrophages after 72 hrs by MTT assay2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and biological evaluation against Leishmania amazonensis of a series of alkyl-substituted benzophenones.
AID351876Binding affinity to Mycobacterium tuberculosis His4-tagged recombinant CYP51 substrate binding site expressed in Escherichia coli HMS174(DE3) by UV-visible spectral titration method2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.
AID475504Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID351878Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 100 uM after 4 days by alamar blue assay2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography.
AID305979Antimycobacterial activity against Mycobacterium smegmatis mc2155 after 48 hrs by microdilution resazurin assay2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
AID345022Binding affinity to human telomerase P2b RNA by STD NMR2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Bioavailability (1)

ArticleYear
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue: 5
2007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]